MASH/MASLD
Laboratory Services
Laboratory Services
Central Lab Services
Medpace specializes in the design and conduct of global trials in gastroenterology and hepatology, including metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) (formerly known as non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD)).
- A2 Macroglobulin
- Adiponectin Total
- Aldolase
- ANGPTL3
- ANGPTL4
- Anti TPO
- Apo A1
- Apo B
- Apo B 48
- Apo B 100
- Apo CII
- Apo CIII
- APR Calculation
- Autotaxin
- Beta Hydroxybutyrate
- Bile Acids Fraction
- Bile Acids Total
- C4 (7-alpha)
- C Peptide
- Chylomicrons
- CK18 M30
- CK18 M65
- Cortisol Salivary
- CRP, hs
- CTX Beta Crosslaps
- Cystatin C
- D Dimer
- ELF Panel
- Ferritin
- FIB4 Calculation
- Fibrinogen
- Fibronectin
- Fibrotest
- FGF-19
- FGF-21
- Free Fatty Acids
- Free Glycerol
- Fructosamine
- G6PD
- Ghrelin
- Glucose
- GLP-1 Active
- GLP-1 Total
- Hyaluronic Acid
- Haptoglobin
- IL1 beta
- IL6
- Insulin
- Lactate
- Leptin
- Lp(a)
- Lipid Panel
- MCP-1
- NAFLD Calculation
- NAS Calculation
- NASH SNP panel by qPCR
- NMR
- P1NP
- PIIINP
- Phosphatidylethanol
- Pro BNP
- Pro C3
- Proinsulin
- Pyruvic Acid
- Resistin
- sLDL
- TGF Beta 1
- TIMP-1
- TNF alpha
- Troponin I
- Vitamin D 25 OH
- YKL-40
Lab Talk: Histology & Anatomic Pathology
Histology & Anatomic Pathology Services
Medpace’s histology services complement the central lab’s continually expanding molecular and flow cytometry capabilities to help Medpace manage MASH & MASLD clinical trials. We have been proactive in implementing testing capabilities that match the spectrum of gastroenterology and hepatology clinical development approaches needed to support pharmaceutical industry partners.
- H&E staining
- Special stains (e.g. Trichrome, Reticulin)
- IHC (e.g. PD-L1 SP263, PD-L1 22C3, HER2, ER, PgR)
- ISH (e.g. HER2)
- Whole slide digital imaging capability
- LDT assays for exploratory biomarker development/research
- Macrodissection capability intended for downstream molecular assays
- Central pathology review by board-certified pathologists with subspecialty expertise